Bearish count just to show that I know it's possible
Green boxes for green abc
Blue boxes for blue ABC
I can update this into less scenarios and clean up the future price targets IF and WHEN wave B finishes. I don't know where that will be but if the price data confirms it, it'll give tagets for C before lift off.
Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality.
The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle...
Continuing from previous post... It is safe to assume the area of 49-50 has strong support due to multiple down days bouncing back off those price levels. We finally broke through resistance at 53-54 levels but risk a gap-fill. Any dips below 53 should be momentary and needs to close above to continue upwards.
Using fib-extensions from Mar 6 and Mar 28, I've...
Retraced from highs and lows within the last 12 months and found the current price to be within an important zone... Above 50 is always a good sign and will eventually push if it holds. Line below price is it's support level. Under would reverse this.
GBT: Global Blood Therapeutics, Inc.
GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
Global Blood Therapeutics’ candidate (Voxelotor) has a lot of potential for SCD.
There are a lot of articles on Sickle Cell Disease (SCD) which I strongly invite you to read.
From a Technical Analysis point of view, I like what I see in GBT's chart.
For me, the stock ended an a-b-c correction and is now preparing to move forward.
Confirmation is needed but...
I'll start this off with I have 0 positions in this company - only came across the ticker doing intra-day scans. I'll start with the most recent huge volume - peeped the news - apparently homeguy H.C Wainwright gives a $120 price target. Was trading $38.70 day before so I'm thinking this mf (since it's a biotech) got FDA approval on high blood pressure treatment...
This stock has a great outlook in regards to bullish fundamentals. I chose this demand level and my order is as follows:
Entry : 18.63
Stop : 16.10
I am looking to hold this for a month or so with exit orders:
Target 1 : 20.17
Target 2 : 21.70